SENSible Question: How Secure a Mitochondrial “Backup” is Allotopic Expression?

A supporter asks if “backing up” copies of the mitochondrially-encoded genes in the nucleus is really viable, granted free radical damage in the nucleus. We emphasize the many additional ways that the nuclear copies will be safer than the mitochondrial originals, that the “backup copies” can be backed up again, and how they and additional strategies will buy us time for even better solutions.

Read more...

Legs of Iron, Feet of Clay

Aging muscles lose strength above and beyond what would be expected from the mere loss of muscle mass. Accordingly, many drugs have been shown to stimulate muscle growth in older people, but the increased muscle mass consistently fails to translate into increased strength and physical function. To let people live independent lives for longer, we need damage-repair longevity therapeutics to repair the cellular and molecular damage that makes aging muscle dysfunctional.

Read more...

Get the Message: mRNA to Target Intracellular Aggregates

Several pharma companies are currently running clinical trials on damage-repair therapies targeting damaged forms of the protein tau to combat Alzheimer’s disease. But these AmyloSENS therapies only reach tau in the fluid outside of neurons, when what we need is to clear damaged tau inside of them. Fortunately, researchers are beginning to use mRNA — the same revolutionary biotechnology platform of the best COVID vaccines — to develop new LysoSENS therapies to do just that.

Read more...

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

The Phase III trials for AmyloSENS rejuvenation biotechnologies lecanemab/Leqembi® and donanemab showed that they are most effective when given to people with less of other kinds of cellular and molecular aging damage in their brains. New data illustrates that fact even more powerfully and gives us a foreshadowing of what’s possible if we make best use of these and forthcoming damage-repair longevity therapeutics.

Read more...

Do the Hallmarks of Aging Make SENS? (Part Two)

A supporter asks if the Hallmarks of Aging could effectively be substituted for the seven categories of cellular and molecular damage in the SENS platform. The answer is ‘no,’ because the Hallmarks include both too much and too little, and most importantly because the Hallmarks fail to serve as a roadmap toward the biomedical postponement of aging.

Read more...

Senolytics in Aging Muscle: Could the Cure Be Worse than the Disease?

Skeletal muscles are organized into long fibers, and when a fiber breaks the entire fiber is often lost. This made a supporter worry that senolytic therapies might break a muscle fiber and eliminate precious fibers in aging muscles. It appears that the injury at the heart of the questioner’s worry does not happen in practice.

Read more...

More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can